BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar

Nov 9, 2020

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin. CNSP’s lead drug candidate – Berubicin – is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer, currently considered incurable. Robert LeBoyer, managing director of equity research at Ladenburg Thalmann & Co. Inc., will moderate the discussion. Interested parties may visit https://ibn.fm/WDMxO for more details regarding the webinar.

To view the full press release, visit https://ibn.fm/d6TNZ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

More News

Trump puts himself on the ballot

Sep 17, 2026

Trump puts himself on the ballot

President Donald Trump at a rally in Gastonia, North Carolina, on September 16, 2026. | Brendan Smialowski/AFP via Getty Images This story appeared in The Logoff, a daily newsletter that helps you stay informed about the Trump administration without letting political news take over your life. Subscribe here. Welcome to The Logoff: With fewer than 50 days until the midterm elections, President Donald Trump is hitting the campaign trail.  What’s happening? Trump was in North Carolina last night for his first major post-primary season rally of the 2026 midterms (setting aside the GOP’s unusual midterm convention last week, which wasn’t not a Trump rally).  Republican Michael Whatley will face former North Carolina Gov. Roy Cooper in November for an open US Senate seat. Speaking near Charlotte, Trump urged voters to “pretend I’m on the ticket, because essentially I am.” It’s becoming a familiar refrain for the president, but not necessarily a promising one — polls suggest Trump is deeply unpopular with voters right now, more likely to drag a ticket down than boost it. How else is Trump getting involved in the midterms? Last week, we noted that Trump was beginning to spend from his vast super PAC account to support Republican candidates. Now, we’re getting a better idea of what that spending looks like: As of earlier this week, Trump’s MAGA Inc. super PAC and related entities had booked ads to the tune of $138 million, a number that could continue to grow. MAGA Inc. has around $400 million in the bank, though as the Washington Post reported earlier this month, Trump has a long list of other things he could choose to spend that money on instead of the midterms (such as legal fees, travel, or even his eventual presidential library). Will it make a difference? It’s a whole lot of money. But with not much time left until voters go to the polls and some mail-in ballots already going out — North Carolina voters began receiving theirs earlier this month — the map is looking fairly dire for Republican hopes.  Trump, meanwhile, isn’t doing himself any favors. The fuel shortages caused by the Iran war are only getting worse, as my colleague Caitlin Dewey explained today. Polls suggest he’s picked the wrong side of the AI issue. And voters are still extremely mad about inflation. And with that, it’s time to log off… It’s not every day we get to write about a new cat — in fact, it’s the first time in more than 100 years. But that’s just what scientists found in the Bolivian Yungas Forest, according to a new study published today. The cat, Leopardus tilcayo, is a type of tiger cat, smaller than your average house cat. It’s also quite cute, and you can see pictures of it here. Thanks for reading, have a great evening, and we’ll see you back here tomorrow!

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Central News Today

Central News Today breaks down complex issues with unique perspective, bringing high-quality journalism to millions of readers around the world.

NEWSLETTER